Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
NASDAQ:STRO
Price:
15.6
USD
-0.26%
Market Cap:
$132.9m
Relative Value
The Relative Value of one
STRO
stock under the Base Case scenario is
30.28
USD.
Compared to the current market price of 15.6 USD,
Sutro Biopharma Inc
is
Undervalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
STRO
Relative Value
Base Case
30.28
USD
Undervaluation 48%
Multiples Across Competitors
STRO Competitors Multiples
Sutro Biopharma Inc Competitors
Sutro Biopharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Sutro Biopharma Inc
NASDAQ:STRO
|
133.1m USD | 1.3 | -0.6 | 0.3 | 0.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.7B USD | 6.6 | 166.7 | 16.2 | 23 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.2B USD | 6.6 | 23.8 | 16.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 9.9 | 31.5 | 23.1 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 5.6 | 18 | 13.4 | 15.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD | 3.5 | 18.1 | 12.3 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR | 14.2 | 33.4 | 56.9 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
